{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T16:47:34Z","timestamp":1783356454416,"version":"3.54.6"},"reference-count":146,"publisher":"Elsevier","isbn-type":[{"value":"9780128122266","type":"print"}],"license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"DOI":"10.1016\/bs.podrm.2017.02.003","type":"book-chapter","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T23:16:33Z","timestamp":1492038993000},"page":"125-192","source":"Crossref","is-referenced-by-count":18,"title":["Gliclazide"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2017.02.003_bb0005","unstructured":"British Pharmacopoeia, Monograph: Medicinal and Pharmaceutical Substances, vols. I and II, Medicines & Health Products Regulatory Agency, UK, 2013, pp. 1022\u20131023."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0010","series-title":"Clark's Analysis of Drugs and Poison","first-page":"640","year":"2004"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0015","series-title":"Martindale: The Extra Pharmacopeia","first-page":"320","year":"1999"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0020","series-title":"Monograph","first-page":"2096","author":"European Pharmacopoeia","year":"2008"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1051\/jbio\/2001195040391","article-title":"Antioxidant and anti-age therapeutics: evaluation and perspectives","volume":"195","author":"Bonnefont-Rousselot","year":"2001","journal-title":"J. Soc. Biol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0030","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1056-8727(00)00084-2","article-title":"In vitro and in vivo antioxidant properties of gliclazide","volume":"14","author":"O'Brien","year":"2000","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0035","first-page":"638","article-title":"The effects of insulin and gliclazide therapy on endoplasmic reticulum stress and insulin sensitivity in liver of type 2 diabetic rats","volume":"51","author":"Sun","year":"2012","journal-title":"Zhonghua Nei ke Za Zhi"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0040","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1463-1326.2012.01644.x","article-title":"Role of K(ATP) channels in \u03b2-cell resistance to oxidative stress","volume":"14","author":"Drews","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0045","doi-asserted-by":"crossref","first-page":"30342","DOI":"10.1155\/2012\/230342","article-title":"Protective effects of beta glucan and gliclazide on brain tissue and sciatic nerve of diabetic rats induced by streptozosin","volume":"2012","author":"Alp","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0050","first-page":"14","article-title":"Comparative characteristics of antioxidant properties of hypoglycemic agents diabenol and gliclazide","volume":"74","author":"Spasov","year":"2011","journal-title":"Eksp. Klin. Farmakol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0055","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1007\/s11033-011-1323-z","article-title":"Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells","volume":"39","author":"Sliwinska","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0060","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1111\/j.1463-1326.2011.01508.x","article-title":"Treating diabetes today with gliclazide MR: a matter of numbers","volume":"14","author":"Avogaro","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejphar.2011.02.044","article-title":"Effects of gliclazide on endothelial function in patients with newly diagnosed type 2 diabetes","volume":"659","author":"Chen","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cbi.2006.07.006","article-title":"Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells","volume":"162","author":"Sliwinska","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0075","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.metabol.2006.02.005","article-title":"Effects of gliclazide beyond metabolic control","volume":"55","author":"Ceriello","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11010-006-2387-2","volume":"283","author":"Satyanarayana","year":"2006","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/07435800500371805","article-title":"Effect of I-deprenyl and gliclazide on oxidant stress\/antioxidant status and DNA damage in a diabetic rat model","volume":"31","author":"Alper","year":"2005","journal-title":"Endocr. Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0090","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1523-1755.2004.00470.x","article-title":"Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet","volume":"65","author":"Onozato","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0095","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-291X(03)00310-3","article-title":"Gliclazide protects pancreatic \u03b2-cells from damage by hydrogen peroxide","volume":"303","author":"Kimoto","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0100","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1464-5491.2002.00762.x","article-title":"Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes","volume":"19","author":"Fava","year":"2002","journal-title":"Diabet. Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0105","unstructured":"L. Beregi, P. Hugon, J. Duhault, N-Phenylsulphonyl-N'-(3-azabicyclo-alkyl)urea derivatives, 1970, US Patent No. 3501495."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0110","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3184\/030823408X374233","article-title":"Improved synthesis of 1-[hexahydrocyclopenta[c]pyrrol-2(1H)-yl]-3-(4-methylbenzenesulfonyl)urea","volume":"11","author":"Qian","year":"2008","journal-title":"J. Chem. Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0115","unstructured":"D. Che, X. Du, Method for preparing gliclazide and its intermediates, PCT Int. Appl. 2011, 2011054312."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0120","first-page":"74","article-title":"Gliclazide","volume":"C55","author":"Parvez","year":"1999","journal-title":"Acta Crystallogr."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0125","first-page":"259","article-title":"Application of UV spectrophotometric method for analysis of gliclazide in pharmaceutical dosage forms","volume":"3","author":"Singh","year":"2011","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0130","first-page":"338","article-title":"Development and validation of UV spectrophotometric method for the determination of Gliclazide in tablet dosage form","volume":"3","author":"Jamadar","year":"2011","journal-title":"Der. Pharma. Chem."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0135","first-page":"227","article-title":"Spectrophotometric estimation of gliclazide in bulk and pharmaceutical dosage forms","volume":"1","author":"Revathi","year":"2010","journal-title":"Int. Res. J. Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0140","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1463-1326.2008.00894.x","article-title":"The efficacy of self-monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release-based regimen. A multicentre, randomized, parallel-group, 6-month evaluation (DINAMIC 1 study)","volume":"10","author":"Barnett","year":"2008","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0145","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1464-5491.2004.01426.x","article-title":"A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial","volume":"22","author":"Charbonnel","year":"2005","journal-title":"Diabet. Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00592-004-0146-y","article-title":"Comparison of uptitration of gliclazide with the addition of rosiglitazone to gliclazide in patients with type 2 diabetes inadequately controlled on half-maximal doses of a sulphonylurea","volume":"41","author":"Baksi","year":"2004","journal-title":"Acta Diabetol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0155","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/dmrr.444","article-title":"The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium","volume":"20","author":"Okouchi","year":"2004","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0160","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1185\/030079901750120231","article-title":"Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes","volume":"16","author":"Salman","year":"2001","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2337\/diacare.15.8.953","article-title":"Is combination sulfonylurea and insulin therapy useful in NIDDM patients? A metaanalysis","volume":"15","author":"Pugh","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0170","first-page":"99","article-title":"High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin","volume":"37","author":"Matsuda","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0175","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF00581049","article-title":"Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma","volume":"32","author":"Sener","year":"1995","journal-title":"Acta Diabetol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0180","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.jpba.2004.02.025","article-title":"Quantification of gliclazide by semimicro high-performance liquid chromatography: application to a bioequivalence study of two formulations in healthy subjects","volume":"35","author":"Park","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0185","first-page":"375134","article-title":"Bioequivalence study of modified-release gliclazide tablets in healthy volunteers","volume":"2012","author":"Rojanasthien","year":"2012","journal-title":"ISRN Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0190","first-page":"653","article-title":"Liquid chromatography-mass spectrometry method for the determination of gliclazide in human plasma and application to a pharmacokinetic study of gliclazide sustained release tablets","volume":"58","author":"Wang","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0195","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5414\/CPP45175","article-title":"A bioequivalence study of gliclazide based on quantification by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry","volume":"45","author":"Mendes","year":"2007","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0200","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchromb.2007.03.022","article-title":"Development of RP-HPLC method for screening potentially counterfeit antidiabetic drugs","volume":"853","author":"Yao","year":"2007","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0205","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jpba.2006.05.003","article-title":"Application of monolithic column in quantification of gliclazide in human plasma by liquid chromatography","volume":"42","author":"Foroutan","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jaoac\/89.2.319","article-title":"Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations","volume":"89","author":"Berecka","year":"2006","journal-title":"J. AOAC Int."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.chroma.2004.12.097","article-title":"High-performance liquid chromatography with electrochemical detection for analysis of gliclazide in plasma","volume":"1088","author":"Kuo","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0220","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1570-0232(02)00951-0","article-title":"A simple and sensitive HPLC method for determination of gliclazide in human serum","volume":"785","author":"Rouini","year":"2003","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0225","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0731-7085(00)00493-3","article-title":"Ion-pair liquid chromatography technique for the estimation of metformin in its multicomponent dosage forms","volume":"25","author":"Vasudevan","year":"2001","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0230","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/0378-4347(92)80563-6","article-title":"Determination of gliclazide in serum by high-performance liquid chromatography using solid-phase extraction","volume":"583","author":"Noguchi","year":"1992","journal-title":"J. Chromatogr."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0235","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3109\/03639045.2013.763817","article-title":"Development of novel gastroretentive drug delivery system of gliclazide: hollow beads","volume":"40","author":"Awasthi","year":"2013","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0240","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/156720112802650716","article-title":"Development of novel gastroretentive floating particulate drug delivery system of gliclazide","volume":"9","author":"Awasthi","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0245","first-page":"57","article-title":"Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions","volume":"59","author":"Patil","year":"2009","journal-title":"Acta Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0250","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/03639040600920622","article-title":"Comparison of the solubility and dissolution rate between gliclazide solid complex and its nanospheres","volume":"33","author":"Lo","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0255","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jpba.2009.10.019","article-title":"Comparison of ultraviolet detection, evaporative light scattering detection and charged aerosol detection methods for liquid-chromatographic determination of anti-diabetic drugs","volume":"51","author":"Shaodong","year":"2010","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0260","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jaoac\/86.2.209","article-title":"Spectrofluorimetric and spectrophotometric determination of gliclazide in pharmaceuticals by derivatization with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole","volume":"86","author":"El-Enany","year":"2003","journal-title":"J. AOAC Int."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0265","first-page":"521353","article-title":"Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay","volume":"2011","author":"Lakshmi","year":"2011","journal-title":"ISRN Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0270","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12020-010-9383-8","article-title":"Effects of metformin plus gliclazide compared with metformin alone on circulating endothelial progenitor cell in type 2 diabetic patients","volume":"38","author":"Chen","year":"2010","journal-title":"Endocrine"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0275","first-page":"489","article-title":"A new method for safety monitoring of natural dietary supplements\u2013quality profile","volume":"42","author":"Wang","year":"2008","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0280","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1747-0285.2008.00704.x","article-title":"Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin","volume":"72","author":"Seedher","year":"2008","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0285","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00007691-199007000-00016","article-title":"A screening test for detecting sulfonylureas in plasma","volume":"12","author":"Shenfield","year":"1990","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0290","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1208\/s12249-012-9760-0","article-title":"Physicochemical investigations and stability studies of amorphous gliclazide","volume":"13","author":"Jondhale","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0295","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3109\/10837450.2012.723719","article-title":"Characterization, quantification and stability of differently prepared amorphous forms of some oral hypoglycaemic agents","volume":"18","author":"Chadha","year":"2013","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0300","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jchromb.2004.12.018","article-title":"The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma","volume":"817","author":"Aburuz","year":"2005","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0305","first-page":"191","article-title":"Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes","volume":"57","author":"Aggarwal","year":"2002","journal-title":"Pharmazie"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0310","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijpharm.2007.03.047","article-title":"Controlling of systemic absorption of gliclazide through incorporation into alginate beads","volume":"341","author":"Al-Kassas","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0315","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s13318-011-0060-y","article-title":"Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats","volume":"37","author":"Al-Salami","year":"2012","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1358\/mf.2008.30.2.1159652","article-title":"Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in-vitro in healthy and diabetic rats treated with probiotics","volume":"30","author":"Al-Salami","year":"2008","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0325","first-page":"532","article-title":"Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats","volume":"60","author":"Al-Salami","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0330","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF03191026","article-title":"Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats","volume":"33","author":"Al-Slami","year":"2008","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0335","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1248\/cpb.50.1495","article-title":"Eudragit NE30D based metformin\/gliclazide extended release tablets: formulation, characterisation and in-vitro release studies","volume":"50","author":"Arno","year":"2002","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0340","first-page":"400","article-title":"In vivo and in vitro evaluation of a solid dispersion system of gliclazide: PEG 6000","volume":"61","author":"Asyarie","year":"2007","journal-title":"PDA J. PharmSciTech"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0345","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","article-title":"Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide","volume":"23","author":"Brendel","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0350","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2174\/138920009789375388","article-title":"Influence of genetic polymorphisms on the pharmacokinetics and pharmacodynamics of sulfonylurea drugs","volume":"10","author":"Xu","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0355","doi-asserted-by":"crossref","first-page":"770","DOI":"10.5414\/CPP47770","article-title":"Pharmacokinetics and bioequivalence evaluation of gliclazide\/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects","volume":"47","author":"Cho","year":"2009","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0360","first-page":"211","article-title":"Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects","volume":"103","author":"Courtois","year":"1999","journal-title":"Res. Commun. Mol. Pathol. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0365","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1365-2125.2000.00162.x","article-title":"Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian aborigines with type 2 diabetes","volume":"49","author":"Davis","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0370","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/bdd.303","article-title":"Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30mg modified release in healthy volunteers","volume":"23","author":"Delrat","year":"2003","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0375","first-page":"459","article-title":"Effect of binary and ternary solid dispersions on the in vitro dissolution and in-situ rabbit intestinal absorption of gliclazide","volume":"24","author":"El-Maghraby","year":"2011","journal-title":"Pak. J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0380","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2125.2003.01751.x","article-title":"Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation","volume":"55","author":"Frey","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0385","first-page":"BR181","article-title":"Pharmaceutical availability of gliclazide from selected matrix formulation tablets","volume":"11","author":"Hermann","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0390","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/BF02976882","article-title":"Pharmacokinetic and pharmacodynamic characterization of gliclazide in healthy volunteers","volume":"26","author":"Kim","year":"2003","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0395","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/jps.2600731204","article-title":"Pharmacokinetics of gliclazide in healthy and diabetic subjects","volume":"73","author":"Kobayashi","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0400","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1248\/bpb1978.4.436","article-title":"Influence of blood proteins on biomedical analysis. III. Pharmacokinetics and protein binding of gliclazide","volume":"4","author":"Kobayashi","year":"1981","journal-title":"J. Pharmacobiodyn."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0405","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1211\/jpp.59.7.0009","article-title":"In-vitro and in-vivo correlation for two gliclazide extended-release tablets","volume":"59","author":"Mandal","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0410","first-page":"1206","article-title":"Timing of administration of sulfonylurea derivatives","volume":"144","author":"de Smet","year":"2000","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0415","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s12272-010-0310-6","article-title":"Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide","volume":"33","author":"Wu","year":"2010","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0420","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0090-9556(25)07245-9","article-title":"Synthesis of putative metabolites and investigation of the metabolic fate of gliclazide, [1-(3-azabicyclo(3,3,0)oct-3-yl)-3-(4-methylphenylsulfonyl)urea], in diabetic patients","volume":"24","author":"Taylor","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0425","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1113\/jphysiol.2005.097642","article-title":"Activation of KATP channels by H2S in rat insulin-secreting cells and the underlying mechanisms","volume":"569","author":"Yang","year":"2005","journal-title":"J. Physiol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0430","first-page":"341","article-title":"Gliclazide: review of metabolic and vascular action","volume":"20","author":"Alberti","year":"1994","journal-title":"Diabete Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0435","doi-asserted-by":"crossref","first-page":"47","DOI":"10.14341\/probl12194","article-title":"Characterization of pancreatic beta cell receptors binding sulfanilamide drugs","volume":"40","author":"Babichev","year":"1994","journal-title":"Probl. Endokrinol. (Mosk.)"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0440","first-page":"45","article-title":"Reclid effects on carbohydrate, lipid metabolism, lipid peroxidation and hemodynamics in patients with diabetes mellitus type 2","volume":"78","author":"Shustov","year":"2000","journal-title":"Klin. Med. (Mosk.)"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0445","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000056073","article-title":"Effect of KAD-1229, a nonsulfonylurea hypoglycemic agent, on plasma glucose and insulin in streptozotocin-induced diabetic dogs","volume":"62","author":"Misawa","year":"2001","journal-title":"Pharmacology"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0450","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-199915060-00007","article-title":"The use of sulphonylureas in the elderly","volume":"15","author":"Graal","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0455","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0168-8227(86)80007-9","article-title":"Serum gliclazide concentration in diabetic patients. Relationship between gliclazide dose and serum concentration","volume":"2","author":"Shiba","year":"1986","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0460","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0026-0495(03)00215-4","article-title":"Gliclazide modified release: a critical review of pharmacodynamic, metabolic, and vasoprotective effects","volume":"52","author":"Schernthaner","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0465","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/s-0032-1333242","article-title":"Serum concentrations and hypoglycemic effect of gliclazide: crosspovidone solid dispersion on streptozotocin induced diabetic rats","volume":"63","author":"Adibkia","year":"2013","journal-title":"Drug Res. (Stuttg.)"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0470","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2478\/v10007-011-0021-7","article-title":"Dissolution rate enhancement of gliclazide by ordered mixing","volume":"61","author":"Saharan","year":"2011","journal-title":"Acta Pharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0475","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1208\/s12249-011-9709-8","article-title":"Development, optimization, and antidiabetic activity of gliclazide-loaded alginate-methyl cellulose mucoadhesive microcapsules","volume":"12","author":"Pal","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0480","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1208\/s12249-010-9573-y","article-title":"In-vitro, in-vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation","volume":"12","author":"Grbic","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0485","first-page":"7","article-title":"The effect of timing on gliclazide absorption and action","volume":"39","author":"Ishibashi","year":"1990","journal-title":"Hiroshima J. Med. Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0490","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2009.06.007","article-title":"Effect of gliclazide immobilization into layered double hydroxide on drug release","volume":"7","author":"Ambrogi","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0495","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1208\/s12249-010-9441-9","article-title":"Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats","volume":"11","author":"Talari","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0500","first-page":"181","article-title":"Pharmaceutical availability of gliclazide from selected matrix formulation tablets","volume":"11","author":"Hermann","year":"2005","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0505","first-page":"641","article-title":"Medication of the month. Gliclazide modified release (Uni Diamicron)","volume":"58","author":"Scheen","year":"2003","journal-title":"Rev. Med. Liege"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0510","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/jps.10350","article-title":"Study of the solubilization of gliclazide by aqueous micellar solutions","volume":"92","author":"Alkhamis","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0515","first-page":"1117","article-title":"Features of insulin secretion and insulin resistance in newly diagnosed type 2 diabetes of different body mass indices","volume":"89","author":"An","year":"2009","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0520","first-page":"431","article-title":"NIDDM: once-daily intervention for type 2 diabetes mellitus: diaprel MR","volume":"42","author":"Ionescu-T\u012drgoviste","year":"2004","journal-title":"Rom. J. Intern. Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0525","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S1262-3636(07)70107-6","article-title":"Gliclazide at a lower concentration than therapeutic dose increases the sensitivity of insulin secretion to glucose in perfused rat pancreas","volume":"30","author":"Mokuda","year":"2004","journal-title":"Diabetes Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0530","article-title":"Molecular mechanisms of insulin secretion","volume":"28","author":"Bataille","year":"2002","journal-title":"Diabetes Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0535","doi-asserted-by":"crossref","first-page":"S368","DOI":"10.2337\/diabetes.51.2007.S368","article-title":"Sulfonylurea stimulation of insulin secretion","volume":"51","author":"Proks","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0540","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.2337\/diabetes.50.8.1778","article-title":"Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes","volume":"50","author":"Juhl","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0545","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2165\/00003495-200262090-00010","article-title":"Gliclazide modified release","volume":"62","author":"McGavin","year":"2002","journal-title":"Drugs"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0550","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1055\/s-2001-15411","article-title":"Gliclazide mainly affects insulin secretion in second phase of type 2 diabetes mellitus","volume":"33","author":"Ligtenberg","year":"2001","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0555","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2165\/00003495-199346010-00007","article-title":"Gliclazide. An update of its pharmacological properties and therapeutic efficacy in non-insulin-dependent diabetes mellitus","volume":"46","author":"Palmer","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0560","first-page":"172","article-title":"Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in","volume":"124","author":"Zhang","year":"2011","journal-title":"Chin. Med. J."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0565","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2265.2010.03878.x","article-title":"Hydrochloride pioglitazone decreases urinary cytokines excretion in type 2 diabetes","volume":"73","author":"Hu","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0570","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2169\/internalmedicine.33.163","article-title":"Possible gliclazide-induced water retention with azotemia","volume":"33","author":"Kamikubo","year":"1994","journal-title":"Intern. Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0575","first-page":"44","article-title":"Hypoglycemic action and disposition of gliclazide in normal and analbuminemic rats","volume":"304","author":"Imamura","year":"1990","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0580","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2125.2007.02943.x","article-title":"Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination","volume":"654","author":"Elliot","year":"2007","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0585","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2012.06.039","article-title":"Blockers of sulfonylureas receptor 1 subunits may lead to cardiac protection against isoprenaline-induced injury in obese rats","volume":"690","author":"Bao","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0590","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejphar.2012.02.006","article-title":"Differential effects of sulfonylurea derivatives on vascular ATP-sensitive potassium channels","volume":"681","author":"Engbersen","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0595","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4103\/0256-4947.81802","article-title":"Diabetes and Ramadan: an update on use of glycemic therapies during fasting","volume":"31","author":"Ahmed","year":"2011","journal-title":"Ann. Saudi Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0600","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.metabol.2009.12.004","article-title":"Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus","volume":"59","author":"Konya","year":"2010","journal-title":"Metabolism"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0605","first-page":"347","article-title":"Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells","volume":"61","author":"Sliwinska","year":"2010","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0610","first-page":"26","article-title":"Effect of hypoglycemic drugs on hemostasis","volume":"73","author":"Spasov","year":"2010","journal-title":"Eksp. Klin. Farmakol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0615","doi-asserted-by":"crossref","first-page":"390678","DOI":"10.1155\/2012\/390678","article-title":"Gliclazide does not fully prevent 2-deoxy-d-ribose-induced oxidative damage because it does not restore glutathione content in a pancreatic \u03b2-cell line","volume":"2012","author":"Koh","year":"2012","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0620","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1185\/03007995.2011.578245","article-title":"Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study","volume":"27","author":"Aravind","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0625","doi-asserted-by":"crossref","first-page":"734","DOI":"10.3923\/pjbs.2009.734.737","article-title":"In-vivo effects of gliclazide and metformin on the plasma concentration of caffeine in healthy rats","volume":"12","author":"Mohiuddin","year":"2009","journal-title":"Pak. J. Biol. Sci."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0630","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.diabet.2009.01.004","article-title":"Effects of exposure of human islet \u03b2-cells to normal and high glucose levels with or without gliclazide or glibenclamide","volume":"35","author":"Del Guerra","year":"2009","journal-title":"Diabetes Metab."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0635","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s005920070006","article-title":"Mechanisms of acute and chronic hypoglycemic action of gliclazide","volume":"37","author":"da Tos","year":"2000","journal-title":"Acta Diabetol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0640","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2165\/00003495-200464120-00006","article-title":"The role of sulphonylureas in the management of type 2 diabetes mellitus","volume":"64","author":"Rendell","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0645","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1056-8727(02)00272-6","article-title":"Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions","volume":"17","author":"Gribble","year":"2003","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0650","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.biochi.2011.02.008","article-title":"Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamic simulation and docking studies","volume":"93","author":"Banu","year":"2011","journal-title":"Biochimie"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0655","first-page":"444","article-title":"Sulphonylureas in the management of type 2 diabetes during the fasting month of Ramadan","volume":"103","author":"Zargar","year":"2005","journal-title":"J. Indian Med. Assoc."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0660","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1464-5491.2012.03772.x","article-title":"Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population","volume":"29","author":"Juurlink","year":"2012","journal-title":"Diabet. Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0665","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.jacc.2010.04.067","article-title":"Erectile dysfunction and later cardiovascular disease in men with type 2 diabetes: prospective cohort study based on the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation) trial","volume":"23","author":"Batty","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0670","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0675","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.diabres.2006.03.009","article-title":"Association of gliclazide and left ventricular mass in type 2 diabetic patients","volume":"74","author":"Pan","year":"2006","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0680","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0026-0495(03)00212-9","article-title":"Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells","volume":"52","author":"Renier","year":"2003","journal-title":"Metabolism"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0685","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1053\/meta.2001.23297","article-title":"Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein","volume":"50","author":"Mamputu","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0690","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1053\/meta.2000.17825","article-title":"Vascular benefits of gliclazide beyond glycemic control","volume":"49","author":"Jennings","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/bs.podrm.2017.02.003_bb0695","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/j.1742-1241.2012.02903.x","article-title":"Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes","volume":"66","author":"Harashima","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0700","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","article-title":"Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats","volume":"609","author":"Fujimori","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0705","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/1056-8727(94)90050-7","article-title":"Hemobiological properties of gliclazide","volume":"8","author":"Ziegler","year":"1994","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0710","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0168-8227(89)90105-8","article-title":"Inhibitory action of gliclazide on platelet functions","volume":"7","author":"Mizuno","year":"1989","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0715","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1620\/tjem.141.Suppl_693","article-title":"Comparison of gliclazide and glibenclamide treatment in non-insulin-dependent diabetes","volume":"141","author":"Baba","year":"1983","journal-title":"Tohoku J. Exp. Med."},{"issue":"5","key":"10.1016\/bs.podrm.2017.02.003_bb0720","first-page":"531","article-title":"Clinical comparative study on the therapeutic effects of oral hypoglycaemic agents in patients with diabetic retinopathy","volume":"26","author":"Kosaka","year":"1983","journal-title":"J. Jpn. Diab. Soc."},{"key":"10.1016\/bs.podrm.2017.02.003_bb0725","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0168-8227(87)80010-4","article-title":"Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study","volume":"3","author":"Jerums","year":"1987","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"2","key":"10.1016\/bs.podrm.2017.02.003_bb0730","first-page":"295","article-title":"Pharmacological studies on gliclazide: effects of gliclazide on platelet aggregation, adhesion and blood coagulation","volume":"12","author":"Shimizu","year":"1976","journal-title":"Pharmacometrics"}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512517300031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512517300031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:33:50Z","timestamp":1761730430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512517300031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"ISBN":["9780128122266"],"references-count":146,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2017.02.003","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}